EU Approves Shire's Vpriv For Gaucher Disease, As Shortages Of Genzyme's Rival Product Ease
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire's Vpriv gains approval in 30 European countries for Gaucher disease, but competition from rival products looks set to increase.